Clinical Trial

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL).
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2018-03-15; most recent amendment 2026-04-03.
Status change: Recruiting → Active, Not Recruiting 2022-03-14
Status change: Not Yet Recruiting → Recruiting 2018-05-30
Trial Details
NCT Number NCT03467867
Lead Sponsor Georgetown University
Collaborators: Hackensack Meridian Health
Conditions Chronic Lymphocytic Leukemia
Enrollment 25 participants
Start Date 2018-04-26
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-06